IMNM vs. MNKD, CNTA, VIR, MIRM, PRTA, BLTE, MGNX, XNCR, OCUL, and COLL
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include MannKind (MNKD), Centessa Pharmaceuticals (CNTA), Vir Biotechnology (VIR), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), Belite Bio (BLTE), MacroGenics (MGNX), Xencor (XNCR), Ocular Therapeutix (OCUL), and Collegium Pharmaceutical (COLL). These companies are all part of the "medical" sector.
MannKind (NASDAQ:MNKD) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking.
MannKind has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.
MannKind has a net margin of -6.00% compared to MannKind's net margin of -761.92%. Immunome's return on equity of 0.00% beat MannKind's return on equity.
MannKind has higher revenue and earnings than Immunome. MannKind is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
MannKind received 550 more outperform votes than Immunome when rated by MarketBeat users. However, 66.67% of users gave Immunome an outperform vote while only 59.83% of users gave MannKind an outperform vote.
MannKind presently has a consensus target price of $8.00, indicating a potential upside of 90.93%. Immunome has a consensus target price of $32.67, indicating a potential upside of 128.92%. Given MannKind's higher possible upside, analysts clearly believe Immunome is more favorable than MannKind.
49.6% of MannKind shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 3.0% of MannKind shares are owned by insiders. Comparatively, 20.0% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Immunome had 5 more articles in the media than MannKind. MarketBeat recorded 5 mentions for Immunome and 0 mentions for MannKind. MannKind's average media sentiment score of 0.68 beat Immunome's score of 0.00 indicating that Immunome is being referred to more favorably in the news media.
Summary
Immunome beats MannKind on 9 of the 17 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
